ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IDH Immunodiagnostic Systems Holdings Plc

378.00
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immunodiagnostic Systems Holdings Plc LSE:IDH London Ordinary Share GB00B01YZ052 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 378.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Immunodiagnostic Systems Hldgs PLC Update on CEO Appointment (8371X)

24/02/2017 3:31pm

UK Regulatory


Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Immunodiagnostic Systems Charts.

TIDMIDH

RNS Number : 8371X

Immunodiagnostic Systems Hldgs PLC

24 February 2017

Immunodiagnostic Systems Holdings PLC

24 February 2017

Update on CEO Appointment

Immunodiagnostic Systems Holdings plc ("IDS"), a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical market today provides an update following the announcement on 19 January 2017 that Patricio Lacalle would be succeeded by Regis Duval as CEO.

IDS is pleased to confirm that Regis will join on 1 March 2017.

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Full name and age: Regis Jacques Duval (aged 45)

Current Directorships and Partnerships

N/A

Previous Directorships and Partnerships in last five years:

Bio-Rad spol. s.r.o.

Bio-Rad Magyarország Kft.

There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

For further information:

 
 Immunodiagnostic Systems     Tel : +44 (0)191 
  Holdings plc                 519 0660 
 Patricio Lacalle, Chief 
  Executive Officer 
 Paul Martin, Group Finance 
  Director 
 
 
 
 Peel Hunt LLP                Tel : +44 (0)207 
                               418 8900 
 James Steel 
 Oliver Jackson 
 

About Immunodiagnostic Systems Holdings PLC:

The Group's vision is to be a leading solution provider to the clinical laboratory diagnostic market. IDS's strategy is focused on developing, internally and through partnership, its automated assay menu for its proprietary automated immunoassay analyser, the IDS-iSYS system. Internally the Group is focused on developing an endocrinology excellence menu and externally IDS works with partners to develop assay panels in complementary indication fields. The Group sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician office laboratories. IDS has field sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAEZLFLDLFLBBZ

(END) Dow Jones Newswires

February 24, 2017 10:31 ET (15:31 GMT)

1 Year Immunodiagnostic Systems Chart

1 Year Immunodiagnostic Systems Chart

1 Month Immunodiagnostic Systems Chart

1 Month Immunodiagnostic Systems Chart

Your Recent History

Delayed Upgrade Clock